Q2 EPS Forecast for Minerva Neurosciences Lifted by Analyst

Posted by Brenda Bartman on May 20th, 2026

Minerva Neurosciences, Inc (NASDAQ:NERV – Free Report) – Investment analysts at HC Wainwright raised their Q2 2026 earnings estimates for Minerva Neurosciences in a research note issued on Monday, May 18th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.20) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.89 EPS, Q4 2027 earnings at $1.95 EPS and FY2027 earnings at $4.82 EPS.

Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04).

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Friday, March 27th. Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Citizens Jmp initiated coverage on shares of Minerva Neurosciences in a research note on Wednesday, April 15th. They set a “market outperform” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Minerva Neurosciences presently has an average rating of “Hold” and an average price target of $10.50.

Check Out Our Latest Research Report on Minerva Neurosciences

Minerva Neurosciences Trading Down 8.0%

Shares of NASDAQ:NERV opened at $4.36 on Wednesday. The company has a 50 day moving average of $6.33 and a 200 day moving average of $5.19. The stock has a market cap of $203.13 million, a P/E ratio of -0.15 and a beta of -0.08. Minerva Neurosciences has a 12 month low of $1.30 and a 12 month high of $12.46.

Hedge Funds Weigh In On Minerva Neurosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Apella Capital LLC grew its stake in Minerva Neurosciences by 7.8% in the 4th quarter. Apella Capital LLC now owns 42,380 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,066 shares in the last quarter. State Street Corp grew its stake in Minerva Neurosciences by 45.4% in the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 7,500 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Minerva Neurosciences in the 4th quarter worth approximately $36,000. OMERS ADMINISTRATION Corp purchased a new position in Minerva Neurosciences in the 1st quarter worth approximately $62,000. Finally, Cannon Global Investment Management LLC purchased a new position in Minerva Neurosciences in the 1st quarter worth approximately $107,000. Hedge funds and other institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences News Summary

Here are the key news stories impacting Minerva Neurosciences this week:

Positive Sentiment: HC Wainwright sharply raised earnings estimates for several future periods at Minerva Neurosciences, including FY2026, FY2027, and quarterly 2027 forecasts, suggesting a more optimistic long-term outlook for the biopharma company. The firm kept a Neutral rating and a $7.00 price target.
Neutral Sentiment: Minerva Neurosciences announced that CEO Remy Luthringer will participate in the 2026 Jefferies Global Healthcare Conference in New York on June 2-4, which may give the company a chance to highlight its pipeline and strategy. Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Negative Sentiment: The stock recently crossed below its 200-day moving average, a technical signal that can reinforce bearish momentum and weigh on near-term trading. Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average – Here’s Why
Negative Sentiment: Despite the improved estimates, HC Wainwright maintained only a Neutral rating, and the company still faces near-term losses, with FY2026 EPS estimated at negative $0.20 versus a consensus of negative $0.60.

Minerva Neurosciences Company Profile

(Get Free Report)

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.